Zhejiang Wecome Pharmaceutical Company Limited
SZSE:300878.SZ
23.26 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 351.199 | 519.621 | 531.292 | 632.953 | 622.767 | 641.801 | 577.652 | 406.529 | 282.092 | 207.742 | 153.277 | 135.06 |
| Cost of Revenue
| 217.105 | 258.362 | 220.097 | 204.376 | 171.419 | 167.766 | 142.299 | 124.37 | 111.033 | 84.887 | 66.018 | 68.738 |
| Gross Profit
| 134.093 | 261.259 | 311.194 | 428.577 | 451.348 | 474.035 | 435.354 | 282.159 | 171.059 | 122.855 | 87.259 | 66.322 |
| Gross Profit Ratio
| 0.382 | 0.503 | 0.586 | 0.677 | 0.725 | 0.739 | 0.754 | 0.694 | 0.606 | 0.591 | 0.569 | 0.491 |
| Reseach & Development Expenses
| 14.186 | 42.798 | 39.32 | 37.015 | 20.409 | 21.16 | 16.4 | 15.829 | 14.364 | 12.934 | 9.676 | 8.554 |
| General & Administrative Expenses
| 11.272 | 8.214 | 6.928 | 6.476 | 11.89 | -7.907 | -9.459 | -8.18 | 18.702 | 28.645 | 19.964 | 20.628 |
| Selling & Marketing Expenses
| 127.061 | 196.507 | 191.643 | 269.989 | 268.08 | 291.797 | 290.648 | 142.205 | 56.009 | 34.961 | 26.673 | 17.949 |
| SG&A
| 138.333 | 216.4 | 198.571 | 276.465 | 279.97 | 283.89 | 281.188 | 134.025 | 74.712 | 63.606 | 46.637 | 38.577 |
| Other Expenses
| 135.318 | 1.447 | -1.701 | 0.886 | -5.645 | 0.482 | 6.757 | 5.658 | 19.011 | -0.16 | -12.931 | -7.463 |
| Operating Expenses
| 287.836 | 262.871 | 250.366 | 324.302 | 289.504 | 323.504 | 326.639 | 173.526 | 92.971 | 65.639 | 48.165 | 39.996 |
| Operating Income
| -153.743 | -1.904 | 59.452 | 99.142 | 159.039 | 147.103 | 103.393 | 104.868 | 75.558 | 58.107 | 39.43 | 25.104 |
| Operating Income Ratio
| -0.438 | -0.004 | 0.112 | 0.157 | 0.255 | 0.229 | 0.179 | 0.258 | 0.268 | 0.28 | 0.257 | 0.186 |
| Total Other Income Expenses Net
| -4.533 | -3.882 | 3.697 | 0.886 | -0.337 | 0.536 | 0.006 | 6.366 | 19.011 | -0.272 | -13.816 | -7.464 |
| Income Before Tax
| -158.276 | -5.786 | 57.751 | 100.028 | 158.702 | 147.639 | 103.399 | 111.235 | 94.568 | 57.834 | 25.613 | 17.64 |
| Income Before Tax Ratio
| -0.451 | -0.011 | 0.109 | 0.158 | 0.255 | 0.23 | 0.179 | 0.274 | 0.335 | 0.278 | 0.167 | 0.131 |
| Income Tax Expense
| -13.398 | 0.399 | 12.631 | 3.481 | 22.997 | 21.627 | 15.623 | 16.077 | 13.717 | 7.811 | 6.838 | 3.257 |
| Net Income
| -147.426 | -8.039 | 48.81 | 96.495 | 135.816 | 126.013 | 87.777 | 95.158 | 80.851 | 50.024 | 20.722 | 19.748 |
| Net Income Ratio
| -0.42 | -0.015 | 0.092 | 0.152 | 0.218 | 0.196 | 0.152 | 0.234 | 0.287 | 0.241 | 0.135 | 0.146 |
| EPS
| -1.03 | -0.06 | 0.31 | 0.67 | 0.94 | 0.87 | 0.81 | 0.88 | 0.74 | 0.46 | 0.53 | 0.55 |
| EPS Diluted
| -1.03 | -0.06 | 0.31 | 0.67 | 0.94 | 0.87 | 0.81 | 0.88 | 0.74 | 0.46 | 0.53 | 0.55 |
| EBITDA
| -80.866 | 53.237 | 113.725 | 132.189 | 174.925 | 165.82 | 111.893 | 116.58 | 94.702 | 62.97 | 42.89 | 30.337 |
| EBITDA Ratio
| -0.23 | 0.102 | 0.214 | 0.209 | 0.281 | 0.258 | 0.194 | 0.287 | 0.336 | 0.303 | 0.28 | 0.225 |